BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Receivables

Track Freeline Therapeutics Holdings plc's receivables ($2.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.82M
↓ 4.76% YoYΔ $-141000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Freeline Therapeutics Holdings plc Receivables History

Loading

Freeline Therapeutics Holdings plc vs. peers: Receivables Comparison

Loading

Freeline Therapeutics Holdings plc Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

Freeline Therapeutics Holdings plc (FRLN) currently reports a receivables of $2.8M as of September 2023. That compares with $3M in the prior-year period — down 4.8% year over year. Use the charts on this page to explore Freeline Therapeutics Holdings plc's receivables history and peer comparisons.

Freeline Therapeutics Holdings plc's receivables decreased from $3M to $2.8M — a 4.8% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Freeline Therapeutics Holdings plc reported $2.8M in receivables as of September 2023. That compares with $3M in the prior-year period — down 4.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $2.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Freeline Therapeutics Holdings plc, and consider following FRLN for alerts when major investors trade the stock.

Freeline Therapeutics Holdings plc is classified in the Healthcare sector. On receivables, it currently shows $2.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FRLN with unrelated industries.